Increasing health insurance coverage and access to usual source of care necessary to meet targets.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Researchers find a 23% increased risk of death among patients who received a transfusion during surgery or post-operative hospitalization.
The estimated recurrence rate at 10 years was 88.3%, data show.
Benefits in cancer-linked symptoms mediated by lower Impact of Event Scale one month after intervention.
Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.
ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.
The five-year cancer-specific and overall survival rates were 100% and 97.8%, respectively.
Active smoking shortens progression-free and overall survival, study finds.
Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.
Researchers observe a high rate of local disease control with increased progression-free survival.
In a head-to-head trial, patients had similar progression-free survival with pazopanib and sunitinib, but experienced fewer adverse effects.
Renal cancers were found in 5% of patients with autosomal dominant polycystic kidney disease.
Bone metastases shorten progression-free and overall survival, study finds.
Study demonstrates improved disease-specific and overall survival.
Cancer-specific and the cancer-free survival rates were 99% at three and five years.
Risk is threefold greater when compared with partial nephrectomy.
It is associated with a high technical success rate and a low rate of complications; local recurrence rare.
After a median follow-up of 36 months, 98% of patients had no recurrence of small renal tumors.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Biopsy-proven renal cell carcinoma developed in 35 (0.5%) of 6,827 ESRD patients.
The survival advantage over men is greatest among women younger than 42 years.
Kidney cancer patients with both hypertension and diabetes are twice as likely to undergo nephron-sparing surgery as those with neither condition.
The 10-year overall survival rate was 94% for partial nephrectomy compared with 89.7% for radical nephrectomy in patients aged 20-44.
Relative survival rates for patients with advanced renal cell carcinoma have not improved significantly in the era of targeted agents.
Final overall survival data from a phase 3 trial reveal no significant difference between tivozanib and sorafenib.
A team of investigators suggests the use of two new specific targets for preventing metastasis in patients with clear cell renal cell carcinoma.